Leaderboards/Cancer Treatment and Pharmacology

Cancer Treatment and Pharmacology

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Mythili Shastry
Sarah Cannon Research Institute
2
Carrie Printz
Unknown
3
Asbjørn Arvad Jørgensen
Jiangsu Institute of Metrology
4
Carl W. Belger
University of the Witwatersrand
5
Chengshuai Yang
Center for Excellence in Molecular Plant Sciences
6
Paulina Słonimska
Gdańsk University of Technology
7
Nina Lykkegaard Gehr
University of Southern Denmark
8
Samantha Anderer
Evanston Hospital
9
Paul O'Dowd
Royal College of Surgeons in Ireland
10
Jan-Stefan Völler
Unknown

Papers

1
Publication in Nature Communications (2024) [62 citations, W4392854261]
Nature Communications|2024
62 cit.
2
Chemotherapy-Mediated Complications of Wound Healing: An Understudied Side Effect
Advances in Wound Care|2024
49 cit.
3
Click-Capable Phenanthriplatin Derivatives as Tools to Study Pt(II)-Induced Nucleolar Stress
ACS Chemical Biology|2024
7 cit.
4
Publication in Scientific Reports (2025) [1 citation, W4415671178]
Scientific Reports|2025
1 cit.
5
Novel Platinum(II) Tetrazine Complex Capable of Live‐Cell IEDDA Reaction
ChemBioChem|2025
0 cit.
6
Publication in Advances in Medical Sciences (2026) [W7148793391]
Advances in Medical Sciences|2026
0 cit.
7
Publication in CA A Cancer Journal for Clinicians (2026) [W7154994932]
CA A Cancer Journal for Clinicians|2026
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Daniel Muñoz
Association of Chartered Certified Accountants
2
Stefan Agewall
University of Oslo
3
Susanna B. Park
The University of Sydney
4
Chelsea McLean
Johnson & Johnson (Netherlands)
5
Fleur Weeber
The Netherlands Cancer Institute
6
Erika Hamilton
Sarah Cannon
7
Julia A. Beaver
Center for Drug Evaluation and Research
8
Sandra Misale
Johns Hopkins University
9
Mark R. Wildung
Washington State University
10
Hirohito Yamaguchi
China Medical University

Papers

1
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research|2022
171 cit.
2
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Cancer Discovery|2022
138 cit.
3
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
The Breast|2022
133 cit.
4
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nature Medicine|2024
128 cit.
5
Rise of Antibody-Drug Conjugates: The Present and Future
American Society of Clinical Oncology Educational Book|2023
102 cit.
6
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine|2025
94 cit.
7
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Future Oncology|2024
91 cit.
8
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
JAMA Oncology|2022
80 cit.
9
ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
Journal of Clinical Oncology|2022
63 cit.
10
Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer
Cancer Research|2022
60 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Eric P. Winer
University of Vermont
2
S. Vincent Rajkumar
WinnMed
3
Andrew T. McPhail
Curtin University
4
Aimery de Gramont
Institut Hospitalier Franco Britannique
5
Rashmi Kumar
University of London
6
Yi Li
Nanyang Technological University
7
Jos H. Beijnen
The Netherlands Cancer Institute
8
Morie A. Gertz
Medical University of South Carolina
9
Patrick M. Dougherty
The University of Texas MD Anderson Cancer Center
10
Joyce O’Shaughnessy
Baylor University Medical Center

Papers

1
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology|2014
4.9k cit.
2
A simple method for clinical assay of superoxide dismutase.
Clinical Chemistry|1988
4.4k cit.
3
Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
Journal of the American Chemical Society|1971
4.1k cit.
4
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Journal of Clinical Oncology|2000
3.8k cit.
5
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
New England Journal of Medicine|2004
3.7k cit.
6
Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine|2020
3.1k cit.
7
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Journal of Clinical Oncology|2003
2.9k cit.
8
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Journal of Clinical Oncology|2009
2.3k cit.
9
Improved survival in multiple myeloma and the impact of novel therapies
Blood|2007
2.3k cit.
10
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Journal of Clinical Oncology|2005
2.1k cit.

Reagents for Cancer Treatment and Pharmacology

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

RocheEvidence 75

VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

#760-5095 (also 08033706001)
View Evidence →
Agilent/Dako

Estrogen Receptor ?

#M7047
View Evidence →
Cell Signaling TechnologyEvidence 67

Cas9 (S. pyogenes) (7A9-3A3) Mouse Monoclonal Antibody (BSA and Azide Free)

#10612$865
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

NETosis Antibody Sampler Kit

Cited in 5 papers
#90144$509
View Evidence →
DSHBEvidence 68

Tumor Protein P53 Peptide 2

#CPTC-TP53-2
View Evidence →
Agilent/DakoEvidence 63

Progesterone Receptor

#M3569
View Evidence →